ANTX - CIK 0001880438
The table below shows AN2 Therapeutics, Inc.'s income statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| R&D | $24.77M | $40.49M | $54.87M | $28.51M | $16.16M |
| SG&A | $13.34M | $14.07M | $14.76M | $12.75M | $4.67M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Operating income |
| -$38.11M |
| -$56.79M |
| -$69.64M |
| -$42.26M |
| -$21.57M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$35.17M | -$51.32M | -$64.73M | -$40.96M | -$21.54M |
| EPS (diluted) | -$1.16 | -$1.72 | -$2.74 | -$2.79 | -$10.64 |